Radiotherapy is not a well-established option for men with intermediate-risk prostate cancer and further substratification of these patients could help to guide treatment decisions. Researchers have developed a new risk-classification system for intermediate-risk patients undergoing dose-escalated external-beam radiation therapy, but how effective is this system?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Edge, S. B. et al. AJCC Cancer Staging Manual, 7th edition 457–468 (Springer, New York, 2010).
Mohler, J. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl Compr. Canc. Netw. 8, 162–200 (2010).
Kuykendal, A. R. et al. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann. Oncol. 24, 1338–1343 (2013).
D'Ambrosio, D. J. et al. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 67, 1082–1087 (2007).
Vance, S. M. et al. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 83, 940–946 (2012).
Qian, Y. et al. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 81, e135–e142 (2011).
Zumsteg, Z. S. et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2013.03.033.
Castle, K. O. et al. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int. J. Radiat. Oncol. Biol. Phys. 85, 693–699 (2013).
Stoyanova, R. et al. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer 119, 1080–1088 (2013).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Buyyounouski, M. Stratifying intermediate-risk patients for radiotherapy. Nat Rev Urol 10, 438–439 (2013). https://doi.org/10.1038/nrurol.2013.142
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2013.142